JP Morgan Chase
MCRB icon

JP Morgan Chase’s Seres Therapeutics MCRB Stock Holding History

JP Morgan Chase’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,255
Closed -$929K – 6495
2021
Q1 		$929K Buy
+2,255
New +$1.04M ﹤0.01% 4283

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

JP Morgan Chase's MCRB Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Seres Therapeutics (MCRB) in Q2 2026: 3,636 shares worth $28.3K. The stake represents ﹤0.01% of the portfolio and ranks #6629 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in MCRB as recently as Q3 2025.

JP Morgan Chase first reported a position in MCRB in Q2 2015 and has held it in 43 quarters since. The position peaked at $7.12M in Q4 2015. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • JP Morgan Chase held 3,636 shares of Seres Therapeutics worth $28.3K as of Q2 2026.
  • Seres Therapeutics was a new JP Morgan Chase position in Q2 2026.
  • Seres Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6629 holding.
  • JP Morgan Chase first reported a position in Seres Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • JP Morgan Chase's Seres Therapeutics position peaked at $7.12M in Q4 2015.
  • 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.